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INTRODUCTION
A recent PubMed search (done in September 2013) using the 
key word herbal medicinal products (HMPs) gave rise to 30,917 
hits, with about 2700 of them published in 2013. The first (most re‑
cent) 10 papers deal with type II diabetes or diabetic nephropathy, 
comparison between Europe and China on the safety of materials, 
the European Union (EU) herbals directive, plant metabolomics 
in quality assessment, various activities of selected herbs, and 
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ABSTRACT
Research on herbal medicinal products is increasingly published in “Western” scientific journals dedicated primarily to conventional 
medicines. Publications are concerned mainly not only on the issues of safety and interactions, but also on efficacy. In reviews, a 
recurring complaint has been a lack of quality studies. In this opinion article, we present the case of Chinese herbal medicines as an 
example, as they have been extensively used in the global market and increasingly studied worldwide. We analyze the potential reasons 
for problems and propose some ways forward. As in the case of any drug, clinical trials for safety, efficacy, and/or effectiveness are 
the ultimate demonstration of therapeutic usefulness of herbal products. These will only make scientific sense when the tested herbal 
products are authentic, standardized, and quality controlled, if good practice guidelines of evidence‑based medicine are followed, and 
if relevant controls and outcome measures are scientifically defined. Herbal products are complex mixtures, and for such complexity, 
an obvious approach for mechanistic studies is network pharmacology based on omic tools and approaches, which has already begun 
to revolutionize the study of conventional drugs, emphasizing networks, interactions, and polypharmacological features behind the 
action of many drugs.
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integrative nanomedicine.[1‑10] Examples of typical articles pub‑
lished in a Western medical journal are either original papers on 
interaction potential,[11,12] or systemic and general reviews on the 
use of herbal medicines in various conditions,[13,14] on the quality, 
efficacy, and safety,[15] on herb–drug interactions[16,17] or herbal 
side effects, especially in hepatotoxicity.[18] A recurring theme in 
conclusions of these reviews was the lack of adequate scientific 
data to judge efficacy and/or safety and the less‑than‑desirable 
quality of the published data. At least in the Western scientific 
establishment, there is a rather strong impression that research 
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on herbals has been rather haphazard and sporadic, when com‑
pared with conventional medicines, and often also outdated and 
wanting of quality.
CURRENT CONDITION OF HERBAL 
RESEARCH
What is behind the current condition of herbal research?
There are some obvious, although not thoroughly surveyed, 
reasons for the current condition of research on herbals. The 
first is lack of sustainable funding in this area. In the USA, the 
situation is probably improving. Since 1999, National Center for 
Complementary and Alternative Medicine (NCCAM) at National 
Institutes of Health (NIH) has been funded US$ 50‑128.8 million 
per annum, which has been dedicated to complementary and 
alternative medicines including herbal medicines. The above‑men‑
tioned “less‑than‑desirable quality” is also due to lack of funding 
and functional mechanisms for interregional, intersectoral, and 
interdisciplinary collaborations on training and sustaining people 
to do high‑quality herbal research and on dissemination, imple‑
mentation, and further refinement of good practices, resulting in 
the sporadic feature of research and various expertise needed for 
high‑quality herbal medicine research scattered around different 
parts of the world.
Changing research and market for herbal 
medicines – Chinese herbal medicines as an example
There are a number of reasons to think that HMPs have a 
potential to become a significant part of efforts to advance drug 
discovery and development. In particular, pharmacologists shuf‑
fling through recent issues of international journals have certainly 
become aware of an increasing contribution of research from 
China, often dealing with traditional Chinese herbal medicines 
or their components. This mere observation testifies the emphasis 
of the Chinese scientific establishments on the research of their 
2000‑year medicinal heritage.
It has been estimated that total value of the world market 
for herbal products stands at around $83 billion and Europe 
accounts for over 50% of the total.[19] Also, the use of Chinese 
herbal products is a worldwide phenomenon and Europe has a 
long history of their use and research.[20] For instance, in 2008, 
China announced a major economic stimulus package, includ‑
ing an investment of US$ 124 billion in healthcare. Due to the 
deep cultural roots of herbal products in China with its 1.3 bil‑
lion people and the strong commitment of the State to further 
develop their use in both domestic and global settings, it is 
anticipated that in the coming years, a larger global market for 
herbal products will be created.[21] Chinese herbal products are 
important for Europe because after Asia, Europe is the second 
largest import/export market of these products,[20] and in China 
alone, approximately 100,000 herbal formulae and over 11,000 
individual medicinal plants have been documented, which 
are generally hailed as rich natural resources for developing 
new drugs, including new lead compounds and new types of 
multi‑component drugs.[22,23]
Changing attitudes of regulators in the EU and the USA 
toward HMPs
In the EU, HMPs have been granted an official medicine status 
by the European Medicines Agency through legislation in 2001 and 
its Committee on Herbal Medicinal Products was established in 
2004. Since then, more than 100 HMPs have undergone scientific 
assessment, which in most cases have resulted in a regulatory 
status either as a well‑established use or a traditional use. These 
classifications relate to the time a product has been on the market 
in the EU and elsewhere and also to the nature and adequacy of 
scientific evidence.
In the USA, most HMPs still fall under the legislation of bo‑
tanical products, i.e. they are under food legislation. Historically, 
the US Food and Drug Administration (FDA) has been reluctant 
to approve herbal products as prescription drugs due to their com‑
plexity, but this has now changed since Veregen (sinecatechins), 
the first herbal product derived from green tea (綠茶 Lǜ Chá; 
Camellia sinensis), was approved by the FDA in late 2008 for 
certain types of external genital or perianal warts,[24,25] followed by 
Crofelemer approved in December 2012 for the relief of diarrhea 
in HIV/AIDS patients taking antiretrovirals.[23] In 2010, it was 
estimated that approximately 25% of botanical investigational 
new drug (IND) applications submitted to the FDA were derived 
from Chinese herbal medicines.[26] Indeed, as a group of specialist 
FDA officials have concluded, although new botanical drugs pose 
many challenges for both industry and the FDA, these challenges 
can be successfully met.[25] Currently, a number of standardized 
Chinese herbal products have been under clinical trials in the USA, 
including PHY906 (黃芩湯 Huáng Qín Tāng) for cancer patients, 
which has passed a multicenter, open‑label, dose escalation phase 
I/II trial,[27] and Dantonic® (丹參滴丸 Dān Shēn Dī Wán), which 
is undergoing phase III trial for the prevention and treatment of 
stable angina.[28] In addition, after a multicenter trial and a liver 
re‑biopsy study in Asia demonstrating good safety and efficacy 
profiles,[29,30] Fuzheng Huayu is now in a phase II clinical trial for 
patients with hepatitis C–induced liver fibrosis in America.[31] In 
keeping with the positive attitude of the FDA, the NIH also em‑
phasizes the importance of traditional and alternative medicines 
through establishing NCCAM, with a budget of US$ 120.7 million 
for 2013.[32] The industrial sector also reacted to the promising 
prospects of Chinese herbal products. For example, Pfizer and 
GlaxoSmithKline have greatly increased their investments into 
further developments based on Chinese herbal medicines.[33,34]
Why are new approaches needed?
There are several reasons why new approaches are needed 
to tackle challenges in drug development and clinical treatment. 
Possibly the most important reason is the emergence of chronic 
diseases as major causes of morbidity and mortality in devel‑
oped countries and increasingly also in developing countries. 
Most chronic diseases are not single entities. Instead, there are 
usually several etiological factors and multiple mechanisms 
within numerous molecular pathways and networks behind various 
manifestations of the disease.[35,36] Preventing and treating these 
major chronic diseases have led to the use of multiple drugs to 
tackle different targets and various symptoms, which furthermore 
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have been associated with an increasing frequency of adverse 
interactions and side effects.[37] While drug development has 
generated novel drugs (albeit rather slowly), the outcome of drug 
treatment has not improved to an expected extent, judged on the 
basis of risks and benefits. It seems that one of the reasons for 
the less‑than‑satisfactory success of drug development during 
the recent decades has been the single‑target–single‑compound 
or one‑disease–one‑drug paradigm based on the emphasis of 
molecular biological approaches and tools.[38] Molecular biology 
has been extremely successful in finding and pinpointing potential 
drug targets, but the consequent development of exceedingly potent 
and selective compounds has not fulfilled expectations in clinical 
reality. Consequently, it seems desirable to cover multiple targets 
at the same time with multiple active principles, but at a balanced 
and personalized manner.
HERBAL MEDICINES AS MULTI‑TARGET 
DRUGS FOR COMPLEX DISEASES
Herbal medicines are complex drugs with multiple potential 
targets and actions
To treat a complex chronic disease would require covering 
multiple targets, and in conventional drug therapy, this leads 
to polypharmacy. In this light, it has to be stressed that herbal 
medicines, just for the sake of them being based on plant‑derived 
products, are chemically complex mixtures containing multiple 
major and minor constituents with multiple potential targets and 
mechanisms. European tradition has been slow in recognizing 
these new possibilities perhaps because of the currently ongoing 
consolidation of the EU legislation concerning well‑established 
and traditional medicines. Meanwhile, some other traditional medi‑
cines, such as those used in Asia,[39] not only provide invaluable 
knowledge resulting in new Western drugs and drug leads,[40] but 
also highlight different approaches characterized by personalized 
medicine and the use of complex herbal products.[25] Accumulating 
evidence suggests that using omic methods, including genomics, 
transcriptomics, epigenomics, proteomics, metabolomics, etc., to 
revisit traditional medicines will lead to new insights and offer 
opportunities for new types of medicine.[41,42]
What is an appropriate conceptual background?
For complex medicines, the current reductionist ap‑
proach (which has worked admirably with conventional single 
drugs) is ill suited for analyzing the actions and interactions of 
multiple chemicals with multiple targets at different levels of an 
organism. Instead, a systems approach is required, be it called 
systems or network biology, medicine or pharmacology, whose 
“goal is to understand in a precise, predictive manner, how drugs 
modulate cellular networks in space and time and how they impact 
human pathophysiology.”[43] Development of drug–target and 
drug–ligand networks to reveal an essentially polypharmacological 
nature of conventional drugs and the application of the ensuing 
polypharmacology to disease networks have resulted in a new, 
more comprehensive view of drugs as multitarget molecules, with 
often overlapping on‑target and off‑target actions.[44‑46] For this 
concept to be applicable to complex herbal products, one has to 
replace only a multitude of conventional drugs (which is usually 
derived from the database of FDA‑approved drugs) with HMPs 
with multiple components. There are already a few examples of the 
application of network pharmacology in the analysis of multiple 
targets and actions of a specific HMP.[47]
What kind of scientific tools are needed?
The above conceptual background for drugs is still based 
to a large extent on in silico exercises, even if some of its pre‑
dictions have been studied and often successfully proven by 
experiments.[45,46] Models and networks need to be populated by 
experimental data, which come from studies using various omic 
techniques, and naturally by bioinformatics for retrieving, storing, 
and handling of the huge amount of data.
As a legacy of the multibillion dollar human genome se‑
quencing projects, technological innovations have exponentially 
increased affordability of genomic and transcriptomic studies. 
Meanwhile, shotgun proteomics,[48] targeted proteomics,[49,50] and 
multiplexed quantitative proteomics using isobaric tags[51] have 
made the proteomics technology faster, more sensitive, and much 
more affordable than ever before. To illustrate the affordability of 
the metabolomic technology, an international company specialized 
in metabolomic service charges US$ 350 per sample, including 
sample processing, high‑performance liquid chromatography/mass 
spectrometry (HPLC/MS), gas chromatography/mass spectrom‑
etry (GC/MS) analysis, statistical analysis, pathway mapping, and 
data interpretation. Finally, analysis of omic data or integrated data 
from different omic levels can now be addressed using a systems 
biology approach.[52]
The omic techniques are increasingly being used in connec‑
tion with functional screening assays, which are able to measure 
phenotypes, i.e., complex physiological and pathological traits 
and perturbations.[53] A recent analysis suggested that the major‑
ity of recent first‑in‑class drugs are actually developed with the 
help of phenotypic screening assays.[54] It is envisaged that in 
the long run, it is possible to build a screening scheme in which 
various subcellular and cellular assays are used in conjunction 
with most modern analytical data‑rich techniques, e.g. omics, 
imaging, and chemical analytical tools, to enable a comprehen‑
sive screening paradigm. One such example is the suggestion 
to screen complex herbal products with respect to absorption, 
distribution, metabolism, and excretion (ADME) and pharmaco‑
kinetic characteristics in a stepwise manner, envisaged to lead to 
the prediction of pharmacokinetic behavior of a product before 
actual clinical trials.[55]
THE WAY FORWARD
The way forward – GP‑TCM as an example
To promote good practice in the research of traditional Chi‑
nese medicine (TCM), with a particular focus on Chinese herbal 
medicines, the Good Practice in Traditional Chinese Medicine 
Research in the Post‑genomic Era consortium, widely known as 
GP‑TCM, was launched by the European Commission under its 
Seventh Framework Programme (FP7) on 1 May 2009.[56] With 
two of us (QX, TPF) as coordinator and deputy coordinator, re‑
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spectively, this 3.5‑year FP7 coordination action project discussed 
state of the art and produced guidelines for studies of Chinese 
herbal medicines, with an emphasis on using an omic approach. 
The consortium voted confidence in the omic and network phar‑
macology technologies in the research of complex herbal products 
and had their main findings published in the open‑access GP‑TCM 
Journal of Ethnopharmacology special issue.[57,58] For example, 
the consortium noted that an omic approach was granted a patent 
for quality control of complex herbal products in 2003 (Patent 
Cooperation Treaty No.: GB00/00428), was successfully applied 
to control the quality and investigate the mechanisms of action 
of Huangqin Tang (黃芩湯 Huáng Qín Tāng), a Chinese herbal 
medicine formula of four herbs,[27,59,60] and was also explored 
in personalized diagnosis and for rescuing drug discovery.[41,42] 
To ensure sustainable collaborations in the development and 
refinement of good practices beyond the lifespan of GP‑TCM 
(May 2009‑October 2012), the FP7 consortium also led the es‑
tablishment of a new not‑for‑profit organization, known as the 
GP‑TCM Research Association.[61] Launched in April 2012, this 
association has officially succeeded the missions and legacies of 
the FP7 GP‑TCM project since November 2012. It will remain a 
devoted link between Europe, China, and other parts of the world, 
especially dedicated to dissemination, validation, and further 
development of good practice guidelines through interregional, 
interdisciplinary, and intersectoral collaborations.
Search for promising leads and useful assays
As pharmacologists/toxicologists (OP, TPF) and nephrolo‑
gist (QX), we became interested in Chinese herbal medicines for 
different reasons, but all based on evidence. For example, in a 
UK–China collaboration led by King’s College London, anti‑ and 
pro‑fibrotic activities of herbs used in TCM were studied system‑
atically using objective, quantitative, and novel assays, based on 
reports in the literature[62] and also guided by the theories and prac‑
tice of TCM.[63] Extracts of 17 herbal formulae and 11 individual 
herbs as well as 5 herbal compounds were found to be anti‑fibrotic 
and extracts of 3 herbs were found to be pro‑fibrotic.[62,63] Thus, 
there are real activities in herbal entities. The question is how to 
improve the quality of research on herbals, especially complex 
herbal mixtures, so that they can be used more efficaciously and 
more safely.
Another interesting example is our observation on herbal regu‑
lation of angiogenesis. Ginseng (人參 Rén Shēn) is a commonly 
used nutraceutical. Intriguingly, existing literature reports both 
wound‑healing and anti‑tumor effects of ginseng extract through 
opposing activities on the vascular system. To elucidate this ap‑
parently contradictory perplexity, the University of Cambridge 
led an international team and merged a chemical fingerprinting 
approach with a deconstructional study of the effects of pure 
molecules from ginseng extract on angiogenesis.[64,65] A mass 
spectrometric compositional analysis of American, Chinese, and 
Korean ginseng, and Sanqi (notoginseng) revealed distinct “sterol 
ginsenoside” fingerprints, especially in the ratio between a triol, 
Rg1, and a diol, Rb1, the two most prevalent constituents, with 
the dominance of Rg1 leading to angiogenesis, but Rb1 exerting 
an opposing effect. This study explained, for the first time, the 
ambiguity about the effects of ginseng in vascular pathophysiol‑
ogy based on the existence of opposing active principles in the 
extract. Differential gene expression profile of human endothelial 
cells revealed Rg1 promotes angiogenesis via the modulation of 
genes that are involved in cytoskeletal dynamics, cell–cell adhe‑
sion, and migration. Further work demonstrates that Rg1 stimulates 
angiogenesis via endothelial nitric oxide synthase (eNOS)[66] and 
vascular endothelial growth factor through the glucocorticoid re‑
ceptor,[67] while Rb1 and Rg3 inhibit angiogenesis by up‑regulating 
pigment epithelium‑derived factor through the b estrogen recep‑
tor.[68] It is noteworthy that some metabolites of ginsenosides are 
novel inhibitors of breast cancer resistance protein.[69]
Another angiogenesis modulator is Angelica sinensis (當歸 
Dāng Guī), which contains alkylphthalides, ferulic acid, and 
polysaccharides. Previous reports showed that n‑butylidene‑
phthalide (BP), an alkylphthalide derived from the volatile oil of 
Radix A. sinensis (VOAS), exhibited anti‑platelet, anti‑anginal, 
and anti‑cancer activities. We have recently reported that BP 
and VOAS are anti‑angiogenic.[70,71] In contrast, Lam et al.,[72] 
showed that an aqueous extract of Radix A. sinensis (AQAS), 
which contained 60% polysaccharide, was pro‑angiogenic. These 
studies clearly highlight the fact that a single medicinal plant 
contains a variety of bioactive compounds, sometimes with op‑
posite pharmacological activities.
Research at University of Oulu has been especially focused 
on pharmaco/toxicokinetic and safety assessment of HMPs, 
which poses great challenges due to their complex nature. The 
chemogenomic approach could provide important predictions also 
for potential harmful effects, as recently demonstrated for some 
TCM and Ayurvedic medicines by Mohd Fauzi et al.[73] However, 
these essentially in silico predictions have to be confirmed and 
eventually validated by experimental and/or clinical studies, in 
which omic approaches might be invaluable in surveying and 
delineating various toxicities and underlying mechanisms of ac‑
tions.[74] The in vitro metabolism, transport, and interaction assays 
used for conventional drugs under development have been success‑
fully applied and modified for the study of HMPs.[75‑77] However, 
currently, it is possible to predict the behavior or responses of 
the complete HMPs on the basis of their individual components 
only to a limited extent. It is obvious that the presence of multiple 
components will give rise to interactions at all levels of kinetics 
and dynamics of HMPs, for good or bad.
Good practices and a paradigm change in complex herbal 
medicine research are necessary
Based on the above analysis, we are convinced that HMPs are 
both interesting and important. Looking forward, good practices 
and a paradigm change are necessary to study HMPs in a produc‑
tive way. Examples have been set regarding traditional herbal 
medicines by some pioneering groups, and in particular, by the 
GP‑TCM project funded by the EU, establishing the necessary 
framework to facilitate the change. The GP‑TCM Research As‑
sociation is expected to play a major role in moving forward good 
practices in this increasingly important area. To further facilitate 
this, European funding like those provided by the NCCAM in 
the USA will be needed. Admittedly, the one‑disease–one‑drug 
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concept will still benefit by the new approach in that promising 
leading compounds will be identified and used for further devel‑
opment. However, this is not enough because complex chronic 
diseases need complex therapeutic solutions, and complex herbal 
medicines may play a significant role in supplying such solutions 
and lead to efficient and safe prevention and treatment. At least 
they are worthy of a fair trial.
What are the implications of the above perspectives and argu‑
ments to clinical pharmacology? Thus far, clinical trials on HMPs 
have provided a rather indefinite and even bleak view about their 
therapeutic benefits. However, it is quite possible that the current 
gold standard, a placebo‑controlled randomized double‑blinded 
trial, is unable to provide a relevant outcome about medicines 
that are primarily intended for personalized and holistic use, as 
is the case with Chinese herbal medicines. Nonetheless, the FP7 
GP‑TCM project has agreed on a guideline on randomized con‑
trolled clinical trials of Chinese herbal medicines,[78] which should 
serve as a plausible starting point for further development. In any 
case, whatever the form of the clinical trial is, at least the major 
results emanating from omic experiments and systems analyses 
should be considered and incorporated into the design of clinical 
trials, especially regarding relevant surrogate markers as clinical 
endpoint measures and for mechanisms.
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